The much-awaited data of the phase III trial of Bharat Biotech’s Covaxin has finally been released in international medical journal The Lancet, making it the first indigenous vaccine to have published the efficacy in public domain. But, is something missing from the report? Yes, says a Mumbai-based health expert.

Highlights of the study

The paper published in The Lancet confirms the efficacy analysis of phase III trials, through evaluation of 25,800 volunteers, of whom 130 were symptomatic patients with 24 in the vaccine group and the remaining 106 in the placebo group, that demonstrated Covaxin to be effective against COVID-19 with an efficacy of 65.2 per cent against the Delta variant and 77.8 per cent against symptomatic COVID-19. The analysis further stated that Covaxin is 93.4 per cent effective against severe symptomatic COVID-19.